Gain Therapeutics (NASDAQ:GANX) Coverage Initiated by Analysts at Scotiabank

Scotiabank assumed coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Friday, Marketbeat Ratings reports. The brokerage issued a sector outperform rating and a $12.00 target price on the stock.

Several other equities analysts have also issued reports on the company. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm reiterated a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, November 25th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Price Performance

GANX opened at $1.88 on Friday. The stock has a 50-day moving average price of $2.24 and a 200-day moving average price of $1.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The firm has a market cap of $49.87 million, a PE ratio of -1.71 and a beta of 0.14. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.80.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Benedict Financial Advisors Inc. bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at about $35,000. Sprott Inc. bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at about $30,000. Northern Trust Corp grew its stake in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at about $65,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.